Literature DB >> 21572658

Anticataleptic and antiepileptic activity of ethanolic extract of leaves of Mucuna pruriens: A study on role of dopaminergic system in epilepsy in albino rats.

D Champatisingh1, P K Sahu, A Pal, G S Nanda.   

Abstract

OBJECTIVE: To assess the anticataleptic and antiepileptic activity of leaves of Mucuna pruriens in albino rats.
MATERIALS AND METHODS: Haloperidol-induced catalepsy (HIC), maximum electro-shock (MES) method, pilocarpine-induced Status epilepticus (PISE) and single-dose effect of M. pruriens were employed.
RESULTS: M. pruriens (100 mg/kg) had significant anticataleptic and antiepileptic activity in HIC, MES, and PISE.
CONCLUSIONS: M. pruriens extract has the potential to be an anticataleptic and antiepileptic drug. Dopamine and 5-HT may have a role in such activity.

Entities:  

Keywords:  Catalepsy; Mucuna pruriens; dopamine; epilepsy

Year:  2011        PMID: 21572658      PMCID: PMC3081462          DOI: 10.4103/0253-7613.77368

Source DB:  PubMed          Journal:  Indian J Pharmacol        ISSN: 0253-7613            Impact factor:   1.200


Introduction

Catalepsy is a nervous condition characterized by muscular rigidity and fixity of posture regardless of external stimuli as well as decreased sensitivity to pain. Catalepsy can appear in schizophrenia, Parkinsonism, and epilepsy. Symptoms include rigid body, rigid limbs, and limbs staying in the same position when moved.[1] Epilepsy is defined as a group of disorders of central nervous system (CNS) characterized by paroxysmal cerebral dysrhythmia, manifesting as brief episodes (seizures) of loss or disturbances of consciousness with or without characteristic body movement (convulsion), sensory or psychiatric phenomena.[2] Epilepsy is the third most common neurological disorder affecting the worldwide population.[3] The plant Mucuna pruriens (family: Fabaceae) is an annual plant found in India. It has high content of dopamine in seeds. The plant also contains 5-HT.[4] The leaves of M. pruriens (MP) are also reported to contain dopamine.[5] Dopamine is used for treatment of catalepsy.[6] It also acts as a neuroprotective agent in epilepsy.[7] The seeds of MP are reported to possess anti-cataleptic activity.[8] However, literature survey does not reveal any such activity in leaves of MP. Therefore the present study was undertaken to investigate the anti-cataleptic and antiepileptic effects of ethanolic extracts of leaves of MP.

Materials and Methods

Animals

Adult albino rats of either sex (weighing 150-175g) bred in the animal house, Siksha ‘O’ Anusandhan University, Bhubaneswar, were used for this study. Animals were housed under a standard 12 h:12 h light/dark cycle and were provided with food and water ad libitum. Animals were acclimatized to laboratory conditions before testing. Each animal was used once. The experimental protocol was approved by Institutional Animal Ethics committee, SOA University, (reg. no. 1171/c/08/CPCSEA) and the study was conducted according to the CPCSEA guidelines for the use and care of experimental animals.

Preparation of alcoholic extract

The leaves of MP were collected from Chandaka forest near Bhubaneswar after due authentication and were shade dried. The leaf powder was subjected to successive soxhlet extraction for 12 h with petroleum ether followed by chloroform and finally with 95% ethanol. The ethanolic extract thus obtained is used in the study.

Drugs and dosage

The test drug, ethanolic extract of leaves of MP (50, 100, 200 and 400 mg/kg), and standard drugs levodopa (100 mg/kg i.p.), phenytoin (25 mg/kg i.p.), diazepam (5 mg/kg i.p.), haloperidol (1 mg/kg i.p.), and pilocarpine (350 mg/kg i.p.) were suspended or dissolved in distilled water and administered.

Haloperidol-induced catalepsy

Catalepsy was induced with haloperidol (1 mg/kg i.p.) and assessed at 30 min intervals until 120 min by means of a standard bar test. Haloperidol was chosen so that it could elicit a moderate degree of catalepsy.[9] Catalepsy was assessed in terms of points given to imposed position of limbs (front) extended and resting on a 3 and 9 cm high wooden bar (1 cm diameter). The end of catalepsy was considered to occur when both front paws were removed from the bar or if the animal moved its head in an exploratory manner.[10] Levodopa (100 mg/kg) was used as standard treatment. Ethanolic extract of MP was administered to three different groups (n=6 in each group) at a dose of 50, 100, 200 mg/kg p.o. respectively 1 h prior to haloperidol administration.

Scoring methods

If the animal maintained the imposed posture for at least 10 s it was considered to be cataleptic. Stage I – Rat moves normally when placed on the table, score = 0. Stage II – Rat moves only when touched or pushed, score = 0.5. Stage III – Rat placed on the table with front paws set alternately on a 3 cm high block fails to correct the posture in 10 s, score = 0.5, for each paw with a total, score = 1, for this stage. Stage IV – Rat fails to remove when the front paws are placed alternately on a 9 cm high block, score = 1, for each paw with a total score = 2 for this stage.[11]

Maximum electroshock method

MES seizures were evoked through transauricular electrodes with a current of 150 mA for duration of 0.2 s. The ethanolic extract of MP was administered to a group of rats (n=6) in a dose of 100 mg/kg, p.o, 1 h before application of electroshock. The duration of tonic hind limb extensor was noted.[12] The percentage of protection was calculated. Phenytoin (25 mg/kg) was used as standard.

Pilocarpine-induced status epilepticus

The albino rats were divided into group of six each. Status epilepticus was induced by administration of pilocarpine at a dose of 350 mg/kg, i.p. Atropine 1 mg/kg i.p. was administered 30 min prior to pilocarpine to reduce the peripheral cholinergic effects of pilocarpine. The ethanolic extract of MP 100 mg/kg was given orally 1 h before injection of pilocarpine nitrate. The severity of status epilepticus was observed every 15 min till 90 min and thereafter every 30 min till 180 min using the following scoring system. Diazepam (5 mg/kg) was used as standard.[13] Stage 0 – No response. Stage 1 – Fictive scratching. Stage 2 – Tremor. Stage 3 – Head nodding. Stage 4 – Forelimb clonus. Stage 5 – Rearing and falling back.

Statistical Analysis

The data were expressed as mean ± SEM. The results were analyzed by one-way analysis of variance (ANOVA) followed by Dunnett's t-test. P<0.01 was considered as significant.[11]

Results

Effect of the ethanolic extract of leaves of MP on HIC

The cataleptic score in rats treated with ethanolic extract of leaves of MP (100 mg/kg) showed a significant (P<0.01) reduction like levodopa (100 mg/kg) against HIC [Table 1] . The control group showed a maximum cataleptic score of 3.5 after 90 min of haloperidol administration.
Table 1

Anticataleptic effect of Mucuna pruriens (MP) on haloperidol-induced catalepsy in rats.

Anticataleptic effect of Mucuna pruriens (MP) on haloperidol-induced catalepsy in rats.

Effect of ethanolic extract of leaves of MP on tonic hind limb extension in MES

The duration of tonic hind limb extension in rats treated with vehicle was 16.83±0.62 s. The ethanolic extract of leaves of MP showed a significant (P<0.01) reduction in tonic extension phase (4.66±0.46 s) at a dose of 100 mg/kg. It completely abolished the tonic extension phase in three out of six rats (50% protection). At higher doses also the response was similar [Table 2.]
Table 2

Antiepileptic effect of acute administration of the ethanolic extract of leaves of Mucuna pruriens (MP) on maximal electric-shock (MES)-induced seizures in rats.

Antiepileptic effect of acute administration of the ethanolic extract of leaves of Mucuna pruriens (MP) on maximal electric-shock (MES)-induced seizures in rats.

Effect of ethanolic extract of leaves of MP on pilocarpine-induced status epilepticus

The ethanolic extract of leaves of MP (100 mg/kg) significantly (P<0.01) reduced the epileptic score in pilocarpine-induced status epilepticus model as compared to control [Table 3] . Diazepam (5 mg/kg) also significantly reduced the severity of seizures.
Table 3

Antiepileptic effect of ethanolic extract of leaves of Mucuna pruriens (MP) (100 mg/kg) on pilocarpine-induced status epilepticus in rats

Antiepileptic effect of ethanolic extract of leaves of Mucuna pruriens (MP) (100 mg/kg) on pilocarpine-induced status epilepticus in rats

Discussion

The alcoholic extract showed no signs of lethality up to 2000 mg/kg. So initially three doses i.e. 50, 100, and 200 mg/kg were selected for the evaluation of anticataleptic activity using the HIC model. At a dose of 100 mg/kg the ethanolic extract showed a significant reduction (P<0.01) of the cataleptic score. So for the evaluation of MES and PISE, the same dose of 100 mg/kg was used. However, for evaluation of dose-dependent antiepileptic activity, two more doses of 200 and 400 mg/kg were used in MES. The HIC model is used to assess anticataleptic drugs. Inhibition of cataleptic score predicts activity of drug against Parkinson's disease. So the ethanolic extract of MP may be useful in catalepsy.[14] The MES is probably the best validated method for assessment of antiepileptic drugs in general tonic clonic seizure. Inhibition of the MES test predicts activity against seizure and cortical focal seizure. So the MP extract may be useful in generalized tonic clonic and cortical focal seizure.[15] However, this antiepileptic activity is not dose dependent. Status epilepticus induced by pilocarpine-treated rats has served as a useful model of temporal lobe epilepsy and reproduces some of the key features of temporal lobe epilepsy in human beings. Since MP extract significantly (P<0.01) reduces the epileptic score than control, it may be effective in temporal lobe epilepsy.[16] The leaves of MP are reported to contain dopamine and 5-HT. Dopamine is used for treatment of catalepsy. Dopamine acts as a neuroprotective agent in epilepsy. Increased serotonin immunoreactivity has been reported in human epileptic brain tissue resected for the control of epilepsy.[17] 5-HT1A receptors are reduced in the ipsilateral hippocampus in temporal-lobe epilepsy patients.[18] So dopamine and 5-HT might play an important role in the anticataleptic and antiepileptic activity of the ethanolic extract of MP.
  12 in total

1.  The serotonergic innervation of the cerebral cortex in man and its changes in focal cortical dysplasia.

Authors:  S Trottier; B Evrard; J P Vignal; J M Scarabin; P Chauvel
Journal:  Epilepsy Res       Date:  1996-10       Impact factor: 3.045

2.  Is experimental catalepsy properly measured?

Authors:  S Ferré; T Guix; G Prat; F Jane; M Casas
Journal:  Pharmacol Biochem Behav       Date:  1990-04       Impact factor: 3.533

Review 3.  Impact of our understanding of the genetic aetiology of epilepsy.

Authors:  R M Gardiner
Journal:  J Neurol       Date:  2000-05       Impact factor: 4.849

4.  Neuroprotective role of dopamine against hippocampal cell death.

Authors:  Y Bozzi; D Vallone; E Borrelli
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

5.  The pilocarpine model of epilepsy in mice.

Authors:  E A Cavalheiro; N F Santos; M R Priel
Journal:  Epilepsia       Date:  1996-10       Impact factor: 5.864

6.  Neuroprotective effects of the antiparkinson drug Mucuna pruriens.

Authors:  Bala V Manyam; Muralikrishnan Dhanasekaran; Theodore A Hare
Journal:  Phytother Res       Date:  2004-09       Impact factor: 5.878

7.  The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

Authors:  Kurt Rasmussen; Mei-Ann Hsu; Stephen Noone; Bryan G Johnson; Linda K Thompson; Susan K Hemrick-Luecke
Journal:  Schizophr Bull       Date:  2007-07-28       Impact factor: 9.306

8.  Effect of antiparkinson drug HP-200 (Mucuna pruriens) on the central monoaminergic neurotransmitters.

Authors:  Bala V Manyam; Muralikrishnan Dhanasekaran; Theodore A Hare
Journal:  Phytother Res       Date:  2004-02       Impact factor: 5.878

9.  Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice.

Authors:  S R Silva; H A Futuro-Neto; J G Pires
Journal:  Neuropharmacology       Date:  1995-01       Impact factor: 5.250

10.  Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study.

Authors:  R Katzenschlager; A Evans; A Manson; P N Patsalos; N Ratnaraj; H Watt; L Timmermann; R Van der Giessen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-12       Impact factor: 10.154

View more
  4 in total

Review 1.  An assessment of potential nutritive and medicinal properties of Mucuna pruriens: a natural food legume.

Authors:  Ruhi Pathania; Prince Chawla; Huma Khan; Ravinder Kaushik; Mohammed Azhar Khan
Journal:  3 Biotech       Date:  2020-05-20       Impact factor: 2.406

2.  Conjugation to Ascorbic Acid Enhances Brain Availability of Losartan Carboxylic Acid and Protects Against Parkinsonism in Rats.

Authors:  Bharat Bhusan Subudhi; Pratap Kumar Sahu; Vijay Kumar Singh; Shaktiketan Prusty
Journal:  AAPS J       Date:  2018-10-22       Impact factor: 4.009

3.  Mucuna pruriens Protects against MPTP Intoxicated Neuroinflammation in Parkinson's Disease through NF-κB/pAKT Signaling Pathways.

Authors:  Sachchida N Rai; Hareram Birla; Saumitra S Singh; Walia Zahra; Ravishankar R Patil; Jyoti P Jadhav; Mallikarjuna R Gedda; Surya P Singh
Journal:  Front Aging Neurosci       Date:  2017-12-19       Impact factor: 5.750

Review 4.  Systematic Overview of Bacopa monnieri (L.) Wettst. Dominant Poly-Herbal Formulas in Children and Adolescents.

Authors:  James D Kean; Luke A Downey; Con Stough
Journal:  Medicines (Basel)       Date:  2017-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.